Virginia K. Clements

8.7k total citations · 4 hit papers
50 papers, 7.1k citations indexed

About

Virginia K. Clements is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Virginia K. Clements has authored 50 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Immunology, 20 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Virginia K. Clements's work include Immunotherapy and Immune Responses (28 papers), Immune cells in cancer (17 papers) and Immune Cell Function and Interaction (14 papers). Virginia K. Clements is often cited by papers focused on Immunotherapy and Immune Responses (28 papers), Immune cells in cancer (17 papers) and Immune Cell Function and Interaction (14 papers). Virginia K. Clements collaborates with scholars based in United States, Sweden and Japan. Virginia K. Clements's co-authors include Suzanne Ostrand‐Rosenberg, Pratima Sinha, Stephanie K. Bunt, Jeff Leips, Minu K. Srivastava, Paulo C. Rodrı́guez, Amy M. Fulton, Steven Μ. Albelda, Daniel W. Beury and Erica M. Hanson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and The Journal of Immunology.

In The Last Decade

Virginia K. Clements

50 papers receiving 7.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine

2009 759 citations Minu K. Srivastava, Pratima Sinha et al. Cancer Research profile →
Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response

2007 679 citations Pratima Sinha, Virginia K. Clements et al. The Journal of Immunology profile →
Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells

2007 599 citations Pratima Sinha, Virginia K. Clements et al. Cancer Research profile →
Reduced Inflammation in the Tumor Microenvironment Delays the Accumulation of Myeloid-Derived Suppressor Cells and Limits Tumor Progression

2007 519 citations Stephanie K. Bunt, Linglin Yang et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Virginia K. Clements United States	34	5.6k	3.1k	1.5k	664	369	50	7.1k
Viktor Umansky Germany	31	4.4k 0.8×	2.9k 0.9×	1.7k 1.2×	605 0.9×	374 1.0×	60	6.3k
Susanna Mandruzzato Italy	36	6.1k 1.1×	3.2k 1.0×	2.0k 1.3×	693 1.0×	403 1.1×	77	7.8k
Yulia Nefedova United States	29	3.9k 0.7×	2.2k 0.7×	1.9k 1.3×	557 0.8×	278 0.8×	53	5.7k
Viktor Umansky Germany	42	3.6k 0.6×	2.8k 0.9×	1.7k 1.2×	625 0.9×	460 1.2×	94	5.6k
Guanjun Cheng United States	25	2.7k 0.5×	1.9k 0.6×	1.3k 0.9×	414 0.6×	501 1.4×	32	4.6k
Pingyan Cheng United States	27	4.0k 0.7×	2.1k 0.7×	1.7k 1.2×	651 1.0×	244 0.7×	40	5.6k
Damya Laoui Belgium	31	3.6k 0.6×	2.3k 0.8×	1.9k 1.3×	858 1.3×	406 1.1×	60	5.5k
Linda A. Snyder United States	25	2.7k 0.5×	2.4k 0.8×	1.5k 1.0×	614 0.9×	564 1.5×	46	4.6k
David Quiceno United States	8	3.4k 0.6×	1.6k 0.5×	867 0.6×	571 0.9×	166 0.4×	10	4.3k
Filippo Veglia United States	14	2.8k 0.5×	1.4k 0.5×	1.1k 0.7×	597 0.9×	349 0.9×	27	4.0k

Countries citing papers authored by Virginia K. Clements

Since Specialization

Citations

This map shows the geographic impact of Virginia K. Clements's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virginia K. Clements with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virginia K. Clements more than expected).

Fields of papers citing papers by Virginia K. Clements

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virginia K. Clements. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virginia K. Clements. The network helps show where Virginia K. Clements may publish in the future.

Co-authorship network of co-authors of Virginia K. Clements

This figure shows the co-authorship network connecting the top 25 collaborators of Virginia K. Clements. A scholar is included among the top collaborators of Virginia K. Clements based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virginia K. Clements. Virginia K. Clements is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Horn, Lucas A., et al.. (2017). Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes. Cancer Immunology Research. 6(1). 59–68. 28 indexed citations

Parker, Katherine H., Pratima Sinha, Lucas A. Horn, et al.. (2014). HMGB1 Enhances Immune Suppression by Facilitating the Differentiation and Suppressive Activity of Myeloid-Derived Suppressor Cells. Cancer Research. 74(20). 5723–5733. 208 indexed citations

Sinha, Pratima, Olesya Chornoguz, Virginia K. Clements, et al.. (2011). Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell–expressed FasL. Blood. 117(20). 5381–5390. 137 indexed citations

Sinha, Pratima, Olesya Chornoguz, Virginia K. Clements, et al.. (2010). Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL (100.18). The Journal of Immunology. 184(Supplement_1). 100.18–100.18. 5 indexed citations

Srivastava, Minu K., Pratima Sinha, Virginia K. Clements, Paulo C. Rodrı́guez, & Suzanne Ostrand‐Rosenberg. (2009). Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine. Cancer Research. 70(1). 68–77. 759 indexed citations breakdown →

Hanson, Erica M., Virginia K. Clements, Pratima Sinha, Dan Ilkovitch, & Suzanne Ostrand‐Rosenberg. (2009). Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells. The Journal of Immunology. 183(2). 937–944. 340 indexed citations

Bunt, Stephanie K., Linglin Yang, Pratima Sinha, et al.. (2007). Reduced Inflammation in the Tumor Microenvironment Delays the Accumulation of Myeloid-Derived Suppressor Cells and Limits Tumor Progression. Cancer Research. 67(20). 10019–10026. 519 indexed citations breakdown →

Sinha, Pratima, Virginia K. Clements, Stephanie K. Bunt, Steven Μ. Albelda, & Suzanne Ostrand‐Rosenberg. (2007). Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response. The Journal of Immunology. 179(2). 977–983. 679 indexed citations breakdown →

Bunt, Stephanie K., Pratima Sinha, Virginia K. Clements, Jeff Leips, & Suzanne Ostrand‐Rosenberg. (2006). Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression. The Journal of Immunology. 176(1). 284–290. 447 indexed citations

10.

Sinha, Pratima, Virginia K. Clements, & Suzanne Ostrand‐Rosenberg. (2005). Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease. The Journal of Immunology. 174(2). 636–645. 359 indexed citations

11.

Sinha, Pratima, Virginia K. Clements, Seth Miller, & Suzanne Ostrand‐Rosenberg. (2005). Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunology Immunotherapy. 54(11). 1137–1142. 91 indexed citations

12.

Ostrand‐Rosenberg, Suzanne, et al.. (2004). Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease. Cancer Immunology Immunotherapy. 53(2). 86–91. 30 indexed citations

13.

Ostrand‐Rosenberg, Suzanne, Virginia K. Clements, Masaki Terabe, et al.. (2002). Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN-γ Dependent. The Journal of Immunology. 169(10). 5796–5804. 95 indexed citations

14.

Ostrand‐Rosenberg, Suzanne, et al.. (1999). Cell‐based vaccines for the stimulation of immunity to metastatic cancers. Immunological Reviews. 170(1). 101–114. 44 indexed citations

15.

Armstrong, Todd D., Virginia K. Clements, & Suzanne Ostrand‐Rosenberg. (1998). Class II-Transfected Tumor Cells Directly Present Endogenous Antigen to CD4+ T Cells In Vitro and Are APCs for Tumor-Encoded Antigens In Vivo. Journal of Immunotherapy. 21(3). 218–224. 31 indexed citations

16.

Laufer, Terri M., S T Smiley, Ann Ranger, et al.. (1997). Single amino acid mutations in the murine MHC class II A beta cytoplasmic domain abrogate antigen presentation. The Journal of Immunology. 159(12). 5914–5920. 8 indexed citations

17.

Baskar, Sivasubramanian, Virginia K. Clements, L H Glimcher, N Nabavi, & Suzanne Ostrand‐Rosenberg. (1996). Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. The Journal of Immunology. 156(10). 3821–3827. 64 indexed citations

18.

Lamousé‐Smith, Esi, Virginia K. Clements, & Suzanne Ostrand‐Rosenberg. (1993). Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.. The Journal of Immunology. 151(11). 6283–6290. 48 indexed citations

19.

Clements, Virginia K., Sivasubramanian Baskar, Todd D. Armstrong, & Suzanne Ostrand‐Rosenberg. (1992). Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. The Journal of Immunology. 149(7). 2391–2396. 56 indexed citations

20.

Ostrand‐Rosenberg, Suzanne, et al.. (1991). Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. The Journal of Immunology. 147(7). 2419–2422. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact